Startseite Technik Chapter 4 Education and training in smart pharma
Kapitel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Chapter 4 Education and training in smart pharma

  • Rishabha Malviya , Shristy Verma , Sonali Sundram und Harshil Shah
Veröffentlichen auch Sie bei De Gruyter Brill
Erkunden Sie dieses Fachgebiet So veröffentlichen Sie bei uns
Digital Blockchain
Ein Kapitel aus dem Buch Digital Blockchain

Abstract

A “connected health” movement is being sparked by the digitalization of healthcare, which also lowers per capita costs, enhances care quality, and improves patient outcomes. The pharmaceutical industry is expanding at a rapid rate due to digitalization, which uses information shared via social media, mobile phones, and other technologies to comprehend consumer demand and optimize supply chain efficiency. Machine learning algorithms can retrieve drug-drug interactions and predict their effects. Big data analysis enables digital health care by eliminating the need for in-person visits and guaranteeing that clinicians have immediate access to all medical records. The physical networking of software, embedded systems, and electronic sensors that permit data sharing across a network from any location is known as the Internet of Things (IoT). The pharmaceutical industry is using blockchain technology to expedite regulatory approval, drug development, and discovery. The Internet of Things is also being used to monitor health problems, predict events about patients, alter data, reduce expenses, and save lives. The chapter offers state-of-the-art training approaches for the smart pharmaceutical industry.

Abstract

A “connected health” movement is being sparked by the digitalization of healthcare, which also lowers per capita costs, enhances care quality, and improves patient outcomes. The pharmaceutical industry is expanding at a rapid rate due to digitalization, which uses information shared via social media, mobile phones, and other technologies to comprehend consumer demand and optimize supply chain efficiency. Machine learning algorithms can retrieve drug-drug interactions and predict their effects. Big data analysis enables digital health care by eliminating the need for in-person visits and guaranteeing that clinicians have immediate access to all medical records. The physical networking of software, embedded systems, and electronic sensors that permit data sharing across a network from any location is known as the Internet of Things (IoT). The pharmaceutical industry is using blockchain technology to expedite regulatory approval, drug development, and discovery. The Internet of Things is also being used to monitor health problems, predict events about patients, alter data, reduce expenses, and save lives. The chapter offers state-of-the-art training approaches for the smart pharmaceutical industry.

Kapitel in diesem Buch

  1. Frontmatter I
  2. Preface V
  3. Foreword VII
  4. Contents IX
  5. Chapter 1 Introduction to smart pharma: foundation of AI and big data 1
  6. Chapter 2 Emerging technology in pharma and the role of AI and blockchain 19
  7. Chapter 3 Partnership and collaboration in the pharmaceutical industry 37
  8. Chapter 4 Education and training in smart pharma 55
  9. Chapter 5 Drug manufacturing and quality control with artificial intelligence 77
  10. Chapter 6 Drug development and clinical trial via artificial intelligence 97
  11. Chapter 7 AI-driven clinical decision support systems for pharma executives 121
  12. Chapter 8 AI-based pharmacovigilance and drug safety 143
  13. Chapter 9 Intellectual property and data privacy in the pharmaceutical sector 163
  14. Chapter 10 Regulatory affairs and compliance in the pharmaceutical sector 183
  15. Chapter 11 AI and big data in post-marketing surveillance 201
  16. Chapter 12 Challenges and ethical considerations 219
  17. Chapter 13 Future trends and innovations of AI in healthcare 237
  18. Index 253
https://doi.org/10.1515/9783111574288-004

Kapitel in diesem Buch

  1. Frontmatter I
  2. Preface V
  3. Foreword VII
  4. Contents IX
  5. Chapter 1 Introduction to smart pharma: foundation of AI and big data 1
  6. Chapter 2 Emerging technology in pharma and the role of AI and blockchain 19
  7. Chapter 3 Partnership and collaboration in the pharmaceutical industry 37
  8. Chapter 4 Education and training in smart pharma 55
  9. Chapter 5 Drug manufacturing and quality control with artificial intelligence 77
  10. Chapter 6 Drug development and clinical trial via artificial intelligence 97
  11. Chapter 7 AI-driven clinical decision support systems for pharma executives 121
  12. Chapter 8 AI-based pharmacovigilance and drug safety 143
  13. Chapter 9 Intellectual property and data privacy in the pharmaceutical sector 163
  14. Chapter 10 Regulatory affairs and compliance in the pharmaceutical sector 183
  15. Chapter 11 AI and big data in post-marketing surveillance 201
  16. Chapter 12 Challenges and ethical considerations 219
  17. Chapter 13 Future trends and innovations of AI in healthcare 237
  18. Index 253
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 23.12.2025 von https://www.degruyterbrill.com/document/doi/10.1515/9783111574288-004/html?lang=de
Button zum nach oben scrollen